Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 -9.39%30 Gross Margin % is 78.44% as of Dec. 2025, which is 26% above its 10-year median of 62.37. GuruFocus rates ROCO:6586 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, CHO Pharma ranks better than 65.44% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. CHO Pharma's Gross Profit for the
six
months ended in Dec. 2025 was NT$0.56 Mil. CHO Pharma's Revenue for the
six
months ended in Dec. 2025 was NT$0.72 Mil. Therefore, CHO Pharma's Gross Margin % for the quarter that ended in Dec. 2025 was 78.44%.
The historical rank and industry rank for CHO Pharma's Gross Margin % or its related term are showing as below:
ROCO:6586'
s Gross Margin % Range Over the Past 10 Years
Min: 47.77 Med: 62.37 Max: 98.33
Current: 74.49
During the past 13 years, the highestGross Margin % of CHO Pharma was 98.33%. The lowest was 47.77%. And the median was 62.37%.
ROCO:6586's Gross Margin % is ranked better than 65.44% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:6586: 74.49
CHO Pharma had a gross margin of 78.44% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CHO Pharma was 0.00% per year.
CHO Pharma (ROCO:6586) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CHO Pharma had a gross margin of 78.44% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CHO Pharma Gross Margin % Related Terms
CHO Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for CHO Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, CHO Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CHO Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CHO Pharma (ROCO:6586) has a Gross Margin % of 78.44% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CHO Pharma and its competitors. This is 26% above median its historical median of 62.37. Over the past decade, CHO Pharma's Gross Margin % has ranged from 47.77 to 98.33. According to the industry distribution chart, CHO Pharma ranks #253 out of 732 companies in the Biotechnology industry, placing it in the top 34.6%.
Is CHO Pharma's Gross Margin % too high?
CHO Pharma's current Gross Margin % of 78.44% is 26% above median its 10-year median of 62.37. Over the past 10 years, this metric has ranged from a low of 47.77 to a high of 98.33. The Biotechnology industry median Gross Margin % is 60.91. CHO Pharma's value of 78.44% is 28.8% above this industry median. Based on the distribution chart, CHO Pharma ranks #253 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CHO Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #253 out of 732 companies for Gross Margin %. This puts CHO Pharma in the upper half of its industry. The industry median Gross Margin % is 60.91. CHO Pharma's value of 78.44% is 28.8% above this benchmark. Historically, CHO Pharma's own Gross Margin % has ranged from 47.77 to 98.33 over the past decade. While the company's 10-year median is 62.37 vs. the industry median of 60.91, CHO Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHO Pharma's current Gross Margin % of 78.44% is 28.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CHO Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current Gross Margin % is 78.44%, which is 26% above median its own 10-year median of 62.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current Gross Margin % of 78.44%. The current Gross Margin % is 78.44%, which is 26% above median its 10-year median of 62.37 and 28.8% above the Biotechnology industry median of 60.91. CHO Pharma's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current Gross Margin % is 78.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
30GF Score
Get the complete analysis for ROCO:6586
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
